
Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that use biological science and technology to discover, develop, and commercialize medicines, therapies, diagnostics, or research tools—ranging from small clinical-stage drug developers to larger integrated biopharma firms. For investors, they tend to be higher-risk and more volatile than broad-market stocks because valuations hinge on clinical trial results, regulatory approvals, and long development timelines, but they can also offer outsized returns if a product succeeds. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Read Our Latest Research Report on VRTX
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read Our Latest Research Report on MRNA
Read More
- MarketBeat’s Top Five Stocks to Own in November 2025
- Is Robinhood’s 11% Post-Earnings Fall a Buy-the-Dip Opportunity?
- AI Demand Is Coming—Is Microchip Technology Ready?
- Why Investors Have Flocked to 2 Unorthodox ETFs This Month
- Rivian’s Chart Says Go, But Some Analysts Still Say No
- e.l.f. Sell-Off Is a Good Time to Buy, According to Analysts
